JP2013503888A - 癌を治療するための化合物および組成物 - Google Patents

癌を治療するための化合物および組成物 Download PDF

Info

Publication number
JP2013503888A
JP2013503888A JP2012528029A JP2012528029A JP2013503888A JP 2013503888 A JP2013503888 A JP 2013503888A JP 2012528029 A JP2012528029 A JP 2012528029A JP 2012528029 A JP2012528029 A JP 2012528029A JP 2013503888 A JP2013503888 A JP 2013503888A
Authority
JP
Japan
Prior art keywords
compound
cell
cancer
independently selected
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012528029A
Other languages
English (en)
Japanese (ja)
Inventor
フォーリー，ミカエル，アンドリュー
ゴウルド，ロバート
エリオット，ピーター
マンディノバ，アナ
リー，サム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Canthera Therapeutics Inc
Original Assignee
General Hospital Corp
Canthera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Canthera Therapeutics Inc filed Critical General Hospital Corp
Publication of JP2013503888A publication Critical patent/JP2013503888A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2012528029A 2009-09-02 2010-09-02 癌を治療するための化合物および組成物 Pending JP2013503888A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27575409P 2009-09-02 2009-09-02
US61/275,754 2009-09-02
PCT/US2010/047615 WO2011028860A2 (en) 2009-09-02 2010-09-02 Compounds and compositions for treating cancer

Publications (1)

Publication Number Publication Date
JP2013503888A true JP2013503888A (ja) 2013-02-04

Family

ID=43625764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012528029A Pending JP2013503888A (ja) 2009-09-02 2010-09-02 癌を治療するための化合物および組成物

Country Status (9)

Country Link
EP (1) EP2473506A4 (zh)
JP (1) JP2013503888A (zh)
KR (1) KR20120104165A (zh)
CN (1) CN102625805A (zh)
AU (1) AU2010289493A1 (zh)
BR (1) BR112012004701A2 (zh)
CA (1) CA2772614A1 (zh)
IN (1) IN2012DN01878A (zh)
WO (1) WO2011028860A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535125A (ja) * 2017-09-18 2020-12-03 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネスＩｎｓｔｉｔｕｔｏ ｄｅ Ｍｅｄｉｃｉｎａ Ｍｏｌｅｃｕｌａｒ Ｊｏａｏ Ｌｏｂｏ Ａｎｔｕｎｅｓ Ｔｒｐｖ２アンタゴニスト

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101629642B1 (ko) 2014-06-25 2016-06-13 서울대학교산학협력단 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물
KR20200081633A (ko) 2018-12-27 2020-07-08 주식회사 티에스디라이프사이언스 피퍼롱구민을 함유하는 담도폐쇄증 치료 또는 예방용 의약 조성물
CN110002987B (zh) * 2019-03-22 2020-09-15 南通大学 苯基亚烯丙基环己烯酮衍生物及制备方法和用途
CN117229205A (zh) * 2023-09-14 2023-12-15 中国医学科学院基础医学研究所 苯基丙烯酰胺类rhbdd1抑制剂制备方法及制药用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2478901A3 (en) 2007-02-14 2012-11-14 Mars Incorporated Neurogenic compounds
EP2135078B1 (en) * 2007-03-09 2013-08-21 DiscoveRx Corporation Methods for identifying agents and their use for the prevention or stabilization of fibrosis
CN102146054A (zh) * 2010-02-10 2011-08-10 新昌县来益科技开发有限公司 荜茇酰胺衍生物及其药物组合物和在制备抑制肿瘤生长的药物中的用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020535125A (ja) * 2017-09-18 2020-12-03 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネスＩｎｓｔｉｔｕｔｏ ｄｅ Ｍｅｄｉｃｉｎａ Ｍｏｌｅｃｕｌａｒ Ｊｏａｏ Ｌｏｂｏ Ａｎｔｕｎｅｓ Ｔｒｐｖ２アンタゴニスト
JP7255785B2 (ja) 2017-09-18 2023-04-11 インスティテュート デ メディシナ モレキュラー ジョアオ ロボ アントゥネス Ｔｒｐｖ２アンタゴニスト

Also Published As

Publication number Publication date
EP2473506A4 (en) 2013-03-06
IN2012DN01878A (zh) 2015-08-21
AU2010289493A1 (en) 2012-04-19
WO2011028860A2 (en) 2011-03-10
CN102625805A (zh) 2012-08-01
KR20120104165A (ko) 2012-09-20
BR112012004701A2 (pt) 2018-06-12
CA2772614A1 (en) 2011-03-10
WO2011028860A3 (en) 2011-07-21
EP2473506A2 (en) 2012-07-11

Similar Documents

Publication Publication Date Title
US8349832B2 (en) Compounds and compositions for treating cancer
US8318737B2 (en) Compounds and compositions for treating cancer
JP4172726B2 (ja) シス―ドコサヘキサエン酸とドセタキセルとの共有複合体を含有する製剤
AU720704B2 (en) Conjugates of cis-docosahexaenoic acid and paclitaxel
TWI679201B (zh) 吡唑并嘧啶化合物
US20080125380A1 (en) Fatty acid-anticancer conjugates and uses thereof
JP6420247B2 (ja) ゲムシタビンプロドラッグ及びその使用
WO2009114126A1 (en) Piperlongumine and piperlongumine analogs for use in the treatment of cancer
EP1313462B1 (en) Use of asiatic acid or asiaticoside for treatment of cancer
US20100129363A1 (en) Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US10604510B2 (en) Solid forms comprising (1E, 4E)-2-amino-N,N-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3H-benzo[B]azepine-4-carboxami compositions thereof, and uses thereof
JP2013503888A (ja) 癌を治療するための化合物および組成物
WO2000067802A1 (en) Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
US20130237539A1 (en) Compounds and Compositions for Treating Cancer
US20060199835A1 (en) Neuroprotective and anti-proliferative compounds
WO2024030960A2 (en) Compositions and methods for inducing ferroptosis
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물